HC Wainwright Reiterates Buy Rating for Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $77.00 price target on the biotechnology company’s stock. Capricor Therapeutics Price Performance Shares of NASDAQ:CAPR opened at $11.61 on Monday. The company’s fifty day moving average price […]
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $77.00 price target on the biotechnology company’s stock. Capricor Therapeutics Price Performance Shares of NASDAQ:CAPR opened at $11.61 on Monday. The company’s fifty day moving average price […]
